The new vaccine took 32 years of research, and cost more than $700 million has been shown to be 40 percent effective at preventing the disease over four years.
When compared to the current process, the new process reduces the time it takes to produce artemisinin concentrate is reduced by 87.5 percent.
The urban malaria vector Anopheles stephensi recently invaded Djibouti and Ethiopia, potentially spreading to other areas of Africa.
An effort to make malaria data available to health workers in Zambia has helped the country to reduce deaths from the disease by 92 percent in the southern region.
Over the next four years, the experiences of these countries will help the WHO determine if RTS,S can be effectively used, and whether it will deliver the nearly 40 percent decrease in malaria infections seen in an earlier Phase 3 clinical trial.To see whether a new malaria vaccine, RTS, is effective, the World Health Organization (WHO) and partners have devised a limited rollout of the vaccine in Malawi followed by Ghana and Kenya.
Researchers demonstrated that mass drug administration can grant community-level protection against Plasmodium falciparum malaria.
The vaccine can confer up to 100 percent protection and will be tested in 2,100 people on the west African island of Bioko.
Instead of using a single protein from the parasite, researchers are using entire parasites—which come with more than 5,000 proteins—deactivated with low doses of radiation.
Scientists have identified a way to provide more detailed information on malaria transmission both locally and across borders.
The Director of the National Center for Disease Control, Badreddine Bashir al-Najjar, confirmed the case in a four-month-old child, adding that tests were underway to determine how she contracted the disease.